Moderna (MRNA) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook gives a ...

The project, which could cost up to $500 billion, was described by Trump as the "largest AI infrastructure project in history." The president said the ... could be used to detect cancers and customize ...

As of February 4 at 1:07:41 PM EST. Market open. Adjusted closing price adjusted for splits and dividend and/or capital gain distributions.

Delving into the details, we found 51% of traders were bullish, while 25% showed bearish tendencies. Out of all the trades we ...

Occasionally, these molecular decoders pause on the mRNA, either because they are instructed to do so or they have difficulty traversing the sequence. Previous studies that investigated these events ...

A complex molecular machine, the spliceosome, ensures that the genetic information from the genome, after being transcribed into mRNA precursors, is correctly assembled into mature mRNA. Splicing is a ...

In the years after the 2020 COVID-19 pandemic, it is clear that mRNA as a modality for vaccines and therapeutics is here to stay based on the number of mRNA programs currently in clinical development.

There have been 67 confirmed human bird flu cases in the U.S. since April 2024. Moderna has been awarded approximately $590 million from the federal government to help speed up the development of ...

It's therefore worth looking at Moderna's earnings history below. Of course, the future is what really matters. NasdaqGS:MRNA Earnings and Revenue Growth January 22nd 2025 Investors should note ...

The firm's mRNA technology was rapidly validated with ... In light of the recent options history for Moderna, it's now appropriate to focus on the company itself. We aim to explore its current ...